Intellia Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Intellia Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2015 to Q3 2024.
  • Intellia Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $154M, a 7.54% increase year-over-year.
  • Intellia Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $581M, a 8.11% increase year-over-year.
  • Intellia Therapeutics, Inc. annual Costs and Expenses for 2023 was $552M, a 8.09% increase from 2022.
  • Intellia Therapeutics, Inc. annual Costs and Expenses for 2022 was $510M, a 69.6% increase from 2021.
  • Intellia Therapeutics, Inc. annual Costs and Expenses for 2021 was $301M, a 54.6% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $581M $154M +$10.8M +7.54% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $570M $146M +$72K +0.05% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $570M $143M +$18.4M +14.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $552M $138M +$14.3M +11.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-22
Q3 2023 $537M $143M +$24.3M +20.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $513M $146M +$33.6M +29.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $479M $125M -$30.9M -19.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $510M $124M +$30.4M +32.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $480M $119M +$39.6M +50% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $440M $112M +$36.8M +48.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $404M $155M +$103M +194% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $301M $93.3M +$44.3M +90.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $257M $79.2M +$28.9M +57.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $228M $75.6M +$26.3M +53.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $201M $52.9M +$6.91M +15% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $195M $49M +$8.29M +20.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-26
Q3 2020 $186M $50.3M +$14.4M +40% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $172M $49.3M +$10.7M +27.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $161M $46M +$11.7M +34.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $149M $40.7M +$12.1M +42.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 $137M $35.9M +$4.44M +14.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 $133M $38.6M +$7.31M +23.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 $126M $34.2M +$4.34M +14.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 $121M $28.6M -$2.76M -8.79% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 $124M $31.5M +$8.32M +35.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 $116M $31.3M +$9.34M +42.6% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 $106M $29.9M +$10.7M +56% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 $95.7M $31.4M +$14.9M +90.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $80.7M $23.2M +$10.6M +84.6% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 $70.1M $21.9M +$10.8M +96.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 $59.3M $19.2M +$10.7M +126% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27
Q4 2016 $48.6M $16.4M +$9.27M +129% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-14
Q3 2016 $39.4M $12.6M +$7.58M +152% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-14
Q2 2016 $31.8M $11.2M +$6.35M +132% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-14
Q1 2016 $25.4M $8.47M +$5.99M +241% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-14
Q4 2015 $19.5M $7.18M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-14
Q3 2015 $4.99M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-14
Q2 2015 $4.8M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-14
Q1 2015 $2.48M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.